Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Docetaxel, Lycopene
Drug · Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Orange, California
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
Interventions
PET imaging with CuATSM, PET imaging, PET CuATSM
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-BBN, 67Cu-SAR-BBN
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Grand Rapids, Michigan + 3 more
Active, not recruiting Phase 2 Interventional

PSMA PET Imaging of Recurrent Prostate Cancer

NCT03204123
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Ga-HBED-iPSMA PET, PET/CT, MRI
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Completed No phase listed Observational

Pain in Cancer Survivors

NCT00581724
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer
Interventions
Telephone interview or self report survey.
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumors, Adenocarcinoma of the Prostate
Interventions
Alisertib, Docetaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Indianapolis, Indiana • Portland, Oregon • San Antonio, Texas + 1 more
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAS0612
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Procedure · Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Biochemical Recurrent Prostate Cancer
Interventions
Isoflavone
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
Interventions
Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington
Completed Not applicable Interventional Results available

PET Scan in Treating Patients With Metastatic Prostate Cancer

NCT00002981
Conditions
Prostate Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18, methionine C 11
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 120 Years · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer, Kidney Cancer
Interventions
High intensity approach, Low intensity approach
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Chambersburg, Pennsylvania
Conditions
Prostate Cancer
Interventions
quality-of-life assessment
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Iowa City, Iowa + 10 more
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions
Pembrolizumab, 177Lu-PSMA-617
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
Conditions
Prostate Cancer
Interventions
Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Radiation · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Conditions
Prostate Cancer
Interventions
SU011248
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
Docetaxel, Prednisone, LDE225
Drug
Lead sponsor
Martin Gutierrez
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Prostate Cancer, Head and Neck Cancers, Upper Abdomen Cancers
Interventions
Research CBCT
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Jacksonville, Florida
Conditions
Solid Tumor
Interventions
Selinexor, Acetaminophen
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
Conditions
Prostate Cancer
Interventions
Focal prostate brachytherapy with Cesium-131
Radiation
Lead sponsor
Ronald M. Benoit, MD
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania